News

The data from the SAkuraStar study on satralizumab add to the total literature on the Genentech humanized monoclonal antibody, which is set for FDA decision later this year.

Finkel discussed his new role at St. Jude Children’s Research Hospital, where he'll head up the new Center for Experimental Neurotherapeutics.

Evidence continues to increase on the neurological impacts of COVID-19 infection, with patients admitted to the intensive care unit (ICU) showing brain abnormalities on MRI scans.

Automated Imaging Differentiation in Parkinsonism (AID-P) outperformed both the Magnetic Resonance Parkinsonism Index and neurofilament light chain protein in differentiating PD from atypical parkinsonism.

Pharmazz, the developer of the endothelin-B receptor agonist, noted that it plans to move forward with an investigational new drug submission to the FDA for sovateltide.

The neurologist at the Barrow Neurological Institute spoke to the impact that social media and telemedicine have had on the medical community’s ability to stay connected and continue to provide care and support.

Amid swirling reports of associations between stroke and the novel coronavirus, as well as the impact the pandemic has had on stroke care, new recommendations to maintain care expectations have been suggested by a diverse group of stroke experts.

Avadel seeks to have its sodium oxybate agent be the first once-nightly therapy to address both excessive daytime sleepiness and cataplexy in patients with narcolepsy.

The neurologist at Banner-University Medicine Neuroscience Institute offered his perspective on data from an open-label safety assessment of cannabidiol (Epidiolex) in the treatment of tuberous sclerosis complex.

The director of the Stroke Center at Banner-University Medicine Neuroscience Institute discussed the possible link between COVID-19 and stroke and offered an update on recent research in the stroke care landscape.

Helius’s short-term treatment PoNS device has been approved for use in Canada, and is intended to be used alongside physical therapy for gait deficit due to mild and moderate symptoms of MS.

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of an analysis from the ACHIEVE studies of ubrogepant.

Despite patients being off treatment for an average of 23 months, patients treated with Eisai’s BAN2401 remained amyloid PET negative in an open-label extension preliminary analysis.

System interventions could be used to modify patient behavior, leading to improved adherence and better clinical outcomes for those with sleep-disordered breathing, according to new data.

The professor of neurology at NYU Langone gives her input on those who are nervous to take hospital trips, as well as the protocol for patients with neurological disorders as COVID-19 slows down.

The FDA-approved treatment was associated with a clinically meaningful delay in needing continuous ventilation among patients with Duchenne muscular dystrophy.

The neurologist at the Barrow Neurological Institute discussed how to best address telemedicine appointments and exams for patients who may be at risk for a fall or some other safety concern.

Data suggest that discrepancies in genetic testing for epilepsy warrant second opinions for interpretations as well as clinical reports that become part of a patient’s medical record following a second opinion.

The trio of authors from Johns Hopkins discussed the findings of a study that imply that BMI is associated with accelerated rates of ganglion cell and inner plexiform layer atrophy in those with multiple sclerosis.